Loading Sign Up for
Dosing
Reminders Loading

Indication

NGENLA is a prescription medicine that contains a form of human growth hormone, like the growth hormone made by the human body, for children 3 years of age and older who are not growing because of low or no growth hormone levels.

Thank you for signing up!
Now you'll get the latest NGENLA information delivered straight to your inbox. A welcome email is on its way. If you have not received this email after a few minutes, please check your junk or spam folder.
Back to HomepageLoading

Important Safety Information & Use

Important Safety
Information & Use

INDICATION
NGENLA is a prescription medicine that contains a form of human growth hormone, like the growth hormone made by the human body, for children 3 years of age and older who are not growing because of low or no growth hormone levels.
IMPORTANT SAFETY INFORMATION
Do not use NGENLA if:
  • your child has a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems.
  • your child is allergic to somatrogon-ghla or any of the ingredients in NGENLA.
  • your child has closed bone growth plates.
  • your child has cancer or other tumors.
  • your child’s healthcare provider tells you that your child has certain types of eye problems caused by diabetes.
  • your child has Prader-Willi syndrome, is severely obese, or has breathing problems including sleep apnea (briefly stopping breathing during sleep).
Before using NGENLA, tell your child’s healthcare provider about all of your child’s medical conditions, including if your child:
  • has had heart or stomach surgery, trauma or serious breathing (respiratory) problems.
  • has had a history of problems breathing while they slept.
  • has or has had cancer or any tumor.
  • has diabetes.
  • is pregnant or plans to become pregnant. It is not known if NGENLA will harm your child’s unborn baby. Talk to your child’s healthcare provider if your child is pregnant or plans to become pregnant.
  • is breastfeeding or plans to breastfeed. It is not known if NGENLA passes into breast milk. You and your child’s healthcare provider should decide if they will take NGENLA while breastfeeding.
Tell your child’s healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NGENLA may affect how other medicines work, and other medicines may affect how NGENLA works.

NGENLA may cause serious side effects, including:
  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma or serious breathing (respiratory) problems.
  • serious allergic reactions. Get medical help right away if your child has the following symptoms: swelling of the face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in the chest, sweating.
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your child’s healthcare provider will need to monitor your child for a return of cancer or a tumor. Contact your child’s healthcare provider if your child starts to have headaches, or has changes in behavior, changes in vision, or changes in moles, birthmarks, or the color of the skin.
  • new or worsening high blood sugar or diabetes. Your child’s blood sugar may need to be monitored during treatment with NGENLA.
  • increase in pressure inside the skull. If your child has headaches, eye problems, nausea or vomiting, contact your child’s healthcare provider.
  • your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in the joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs and feet. Fluid retention can happen in children during treatment with NGENLA. Tell your child’s healthcare provider if your child has any of these signs or symptoms of fluid retention.
  • decrease in a hormone called cortisol. Your child’s healthcare provider will do blood tests to check your child’s cortisol levels. Tell your child’s healthcare provider if your child has severe fatigue, dizziness, weakness, vomiting, dehydration, or weight loss.
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well NGENLA works. Your child’s healthcare provider will do blood tests to check your child’s hormone levels.
  • hip and knee pain or limp (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to a lack of blood supply (osteonecrosis). Get medical help for your child right away if your child develops a limp or has hip or knee pain.
  • worsening of curvature of the spine (scoliosis). If your child has scoliosis, your child will need to be checked often for an increase in the curve of the spine.
  • severe and constant stomach (abdominal) pain. This could be a sign of pancreatitis. Tell your child’s healthcare provider if your child has any new abdominal pain.
  • loss of fat and tissue weakness in the area of skin you inject. Talk to your child’s healthcare provider about rotating the areas where you inject NGENLA.
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea.
  • increase in phosphorus, alkaline phosphatase and parathyroid hormone levels in the blood. Your child’s healthcare provider will do blood tests to check this.
The most common side effects (≥5%) of NGENLA include: injection site reactions (such as pain, swelling, rash, itching, bleeding), common cold, headache, fever, low red blood cells (anemia), cough, vomiting, decrease in thyroid hormone levels, stomach (abdominal) pain, rash, throat pain.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

© 2026 Pfizer Inc. All rights reserved. 
PP-SMT-USA-0736